John Brennan Plays the 'Nazi Card' While FBI Turns Up the Heat
Remember the McCloskeys? The Government Finally Gave Back What it Stole From Them.
Marjorie Taylor Greene Is Fed Up With the Republican Party Establishment – She's...
The District Accused This Teacher of 'Hate Bias.' Now They are Paying for...
Adieu and Good Riddance to the Corporation for Public Broadcasting
The Left and Losers
A Quick Bible Study Vol. 279: Moses in the New Testament – Book...
Democrat Calls Lawbreakers 'Long-Term Residents' in Stunning Display of Border Amnesia
America First, Big Pharma Last: Trump Orders Drug Prices Slashed to Lowest Global...
California Homeowners Take Up Arms as Crime Surges Under Newsom, Bass
New App Helps Democrats Tip Off Illegal Immigrants About ICE
Mark Halperin Drops Bombshell: Biden Team Holding 'Embarrassing' Dirt on Harris If She...
Hamas Releases Gruesome Propaganda Video of Starving Israeli Hostage Digging His Own Grave
'Go to Hell': Trump Torches Schumer as Nominee Deal Collapses Over Democrat Demands
Desperate to Cling to Power, Mullah's Executioners Target Political Prisoners
Tipsheet

AstraZeneca COVID Vaccine Trial Exceeds Expectations After Controversy

AP Photo/Kirsty Wigglesworth

Could a fourth COVID vaccine be on the horizon? There's been some controversy and negative coverage of AstraZeneca's shot, developed with the University of Oxford. The European Medicines Agency approved the shot in January, but at least 16 European countries stopped distribution of the vaccine due to concerns about blood clots. About 30 recipients of the vaccine, most of whom were women under the age of 55, were reportedly diagnosed with cerebral venous sinus thrombosis.

Advertisement

But a new U.S. clinical trial of 30,000 people has produced some positive results that may put those fears to rest. The trial "confirmed the safety profile of the vaccine," reports CNBC. The vaccine proved to be 79 percent effective in preventing symptomatic COVID, and 100 percent effective in preventing hospitalization.

The trial included over 30,000 participants and showed that the vaccine had an overall efficacy of 79% in preventing symptomatic Covid-19 and was 100% effective in preventing severe disease and hospitalization.

Efficacy was consistent across age and ethnic group, with 80% efficacy in participants aged 65 years and over. The vaccine, known as AZD1222 and developed with the University of Oxford, was well-tolerated and the independent data safety monitoring board identified no safety concerns related to the vaccine. 

A group of German researchers recently issued a statement connecting the vaccine to a risk of blood clots, but the U.S. trial appeared to upend that assessment.

Advertisement

Health experts say there should now be nothing holding AstraZeneca back from getting the FDA's blessing.

“I can’t see why the regulator wouldn’t approve it,” Adam Barker, healthcare analyst at Shore Capital, wrote.

Three COVID-19 vaccines are currently FDA approved, including those produced by Pfizer-BioNTech, Moderna, and Johnson & Johnson, the last of which only requires one dose.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement